×
The submission system is temporarily under maintenance. Please send your manuscripts to
Go to Editorial ManagerABSTRACT Psoriasis (PSO) is an immune-mediated dermatological disorder marked by thick, erythematous, scaly plaques resulting from rapid, excessive cellular growth. Anti-inflammatory agents, immunosuppressant’s, and additional pharmaceuticals serve as the principal therapeutic strategy for psoriasis to alleviate symptoms, diminish inflammation, and inhibit the proliferation and division of epidermal cells. Nevertheless, these drugs generally include disadvantages that impose significant physiological and pathological burdens on patients, including inadequate targeting, brief half-lives, limited absorption rates, and severe toxic side effects. Researchers have recently concentrated significant effort on employing delivery systems for the topical administration of drugs to affected psoriatic skin regions. These systems increase pharmacological efficacy, stability, and penetration. More therapeutic concepts for the treatment of PSO are made possible by the ongoing development of numerous multifunctional topical delivery technologies. This publication reviews various delivery strategies, including hydrogels, nanoparticles, microneedles, micelles, dendrimers, liposomes, nanoemulsions, and vesicles, for topical therapy of PSO and delineates their current developmental status in clinical treatment. It is expected to facilitate the progression of PSO treatment methodologies and provide a benchmark for the development of novel topical delivery systems.
Diabetic ulcer is a significant medical issue affecting millions of patients globally due to consequential morbidity, mortality, and health care system costs. The complex pathophysiological process of delayed wound healing in diabetic patients remains inadequately addressed with conventional treatment modalities. This review summarises recent advances in smart, responsive engineered drug delivery systems for the treatment of diabetic ulcers. Moreover, we exemplify these strategies using emerging technologies, including nanotechnology, hydrogel matrices, stimulus-responsive systems, and bioactives. New methodologies, including next-generation approaches such as 3D-printed scaffolds, nanofiber systems, and theranostic platforms, are presented as alternative treatment options that could change the landscape of diabetes-related wound care. Discussions on the challenges of translation, regulation, and application of new pharma-technologies in clinical research are offered